155 related articles for article (PubMed ID: 2021530)
1. Pharmacokinetics and cytotoxicity of RSU-1069 in subcutaneous 9L tumours under oxic and hypoxic conditions.
Wong KH; Koch CJ; Wallen CA; Wheeler KT
Br J Cancer; 1991 Apr; 63(4):484-8. PubMed ID: 2021530
[TBL] [Abstract][Full Text] [Related]
2. Effect of administration schedules on the potentiation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) by misonidazole in subcutaneous 9L tumors.
Wong KH; Zhang H; Wallen CA; Wheeler KT
Int J Radiat Oncol Biol Phys; 1992; 23(4):831-9. PubMed ID: 1618675
[TBL] [Abstract][Full Text] [Related]
3. Chemosensitization of the nitrosoureas by 2-nitroimidazoles in the subcutaneous 9L tumor model: pharmacokinetic and structure-activity considerations.
Wong KH; Wallen CA; Wheeler KT
Int J Radiat Oncol Biol Phys; 1990 May; 18(5):1043-50. PubMed ID: 2140824
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution of misonidazole and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in rats bearing unclamped and clamped 9L subcutaneous tumors.
Wong KH; Wallen CA; Wheeler KT
Int J Radiat Oncol Biol Phys; 1989 Jul; 17(1):135-43. PubMed ID: 2745188
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).
Binger M; Workman P
Cancer Chemother Pharmacol; 1991; 29(1):37-47. PubMed ID: 1742848
[TBL] [Abstract][Full Text] [Related]
6. 2-Nitroimidazole potentiation of nitrosourea induced cytotoxicity in subcutaneous implants of rat 9L brain tumor cells.
Wong KH; Wallen CA; Wheeler KT
J Neurooncol; 1991 Aug; 11(1):17-25. PubMed ID: 1833513
[TBL] [Abstract][Full Text] [Related]
7. Studies of the in vivo and in vitro cytotoxicity of the drug RSU-1069.
Hill RP; Gulyas S; Whitmore GF
Br J Cancer; 1986 Jun; 53(6):743-51. PubMed ID: 3755053
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice.
Walton MI; Workman P
Cancer Chemother Pharmacol; 1988; 22(4):275-81. PubMed ID: 3168141
[TBL] [Abstract][Full Text] [Related]
9. Induction of tumour hypoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo.
Stratford IJ; Adams GE; Godden J; Howells N
Int J Radiat Biol; 1989 Mar; 55(3):411-22. PubMed ID: 2564037
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of RSU-1069 tumour cytotoxicity by 5-hydroxytryptamine (5-HT).
Chaplin DJ
Br J Cancer; 1986 Nov; 54(5):727-31. PubMed ID: 3801269
[TBL] [Abstract][Full Text] [Related]
11. Modification of alkylating agent induced cell kill by 2-nitroimidazoles in unclamped and clamped SC 9L tumors.
Wallen CA; Moore SK; Wheeler KT
Int J Radiat Oncol Biol Phys; 1992; 22(4):727-30. PubMed ID: 1531976
[TBL] [Abstract][Full Text] [Related]
12. The radiosensitizing and toxic effects of RSU-1069 on hypoxic cells in a murine tumor.
Chaplin DJ; Durand RE; Stratford IJ; Jenkins TC
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1091-5. PubMed ID: 3755714
[TBL] [Abstract][Full Text] [Related]
13. Hypoxic cells and in situ chemopotentiation of the nitrosoureas by misonidazole.
Wheeler KT; Wallen CA; Wolf KL; Siemann DW
Br J Cancer; 1984 Jun; 49(6):787-93. PubMed ID: 6733024
[TBL] [Abstract][Full Text] [Related]
14. Bioreduction of RSU 1069 and mitomycin C after dearterialization.
Wang LQ; Persson BG; Bengmark S
Eur J Surg Oncol; 1993 Oct; 19(5):455-62. PubMed ID: 8405482
[TBL] [Abstract][Full Text] [Related]
15. High uptake of RSU 1069 and its analogues melanotic melanomas.
Walling JM; Deacon J; Holliday S; Stratford IJ
Cancer Chemother Pharmacol; 1989; 24(1):28-32. PubMed ID: 2541936
[TBL] [Abstract][Full Text] [Related]
16. The chemosensitizing and cytotoxic effects of RSU 1164 and RSU 1165 in a murine tumor model.
Siemann DW
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1115-8. PubMed ID: 2703392
[TBL] [Abstract][Full Text] [Related]
17. Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice.
Cole S; Stratford IJ; Bowler J; Nolan J; Wright EG; Lorimore SA; Adams GE
Int J Radiat Oncol Biol Phys; 1991 Jul; 21(2):387-95. PubMed ID: 2061115
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxicity of RSU 1069 in spheroids and murine tumors.
Olive PL; Durand RE; Chaplin DJ
Int J Radiat Oncol Biol Phys; 1987 Sep; 13(9):1361-6. PubMed ID: 3624045
[TBL] [Abstract][Full Text] [Related]
19. RSU 1069, a 2-nitroimidazole containing an alkylating group: high efficiency as a radio- and chemosensitizer in vitro and in vivo.
Adams GE; Ahmed I; Sheldon PW; Stratford IJ
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1653-6. PubMed ID: 6548211
[TBL] [Abstract][Full Text] [Related]
20. Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas.
Cole S; Stratford IJ; Adams GE; Fielden EM; Jenkins TC
Radiat Res; 1990 Oct; 124(1 Suppl):S38-43. PubMed ID: 2236508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
